Although a limited number of patients enrolled, the TB-IMID cohort showed a similar level of cytokine-producing CD4+ T cells or AIM+ CD4+ T cells compared to TB individuals enrolled before starting the TB therapy. Here, CD4 is linked to tuberculosis.